Literature DB >> 6616979

Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia.

H Masur, P Francioli, M Ruddy, H W Murray.   

Abstract

The pharmacokinetics and toxicity of six week courses of vancomycin were assessed prospectively in 12 chronic hemodialysis patients who had 17 episodes of Staphylococcus aureus bacteremia. Patients were treated with 1 gram doses of vancomycin at weekly intervals for six weeks. Peak serum vancomycin concentrations ranged from 5.5-40.0 micrograms/ml and trough concentrations were 1.0-12.0 micrograms/ml at the time of the second dose. No patients demonstrated important drug accumulation at the time of the fifth dose. Pure tone audiometry demonstrated no auditory toxicity. Flushing and pruritus (two patients) were only adverse effects noted. In 16 episodes blood cultures were sterilized within 48 hours of therapy. This investigation demonstrates that in chronic hemodialysis patients with S. aureus bacteremia vancomycin is a safe and microbiologically effective antimicrobial agent. Peak and trough serum concentrations vary widely when 1 gram doses are given at one week intervals, and thus it is recommended that concentrations be measured for each patient, particularly if the minimum bactericidal concentration of vancomycin for the clinical isolate is greater than 1.0 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616979

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

Review 1.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model.

Authors:  S B Duffull; E J Begg; S T Chambers; M L Barclay
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 4.  Vancomycin ototoxicity and nephrotoxicity. A review.

Authors:  G R Bailie; D Neal
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

5.  Lack of effect of vancomycin and gentamicin on auditory function in guinea pigs.

Authors:  K Nishihara; T Shimizu; H Kotaki; Y Sawada; T Okuno; K Kaga; T Murofushi; T Iga
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.

Authors:  J Böhler; P Reetze-Bonorden; E Keller; A Kramer; P J Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Enhanced clearance of vancomycin by hemodialysis in a child.

Authors:  R Schoumacher; R L Chevalier; R A Gomez; A D Rogol; R Cummings; D A Spyker
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

8.  Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

Authors:  J Alwakeel; T A Najjar; M J al-Yamani; S Huraib; A al-Haider; H Abu-aisha
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

9.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

Review 10.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.